Amino acid modified polypeptides

• US 20040086961A1
• Filed: 03/22/2002
• Published: 05/06/2004
• Est. Priority Date: 06/03/1996
• Status: Active Grant

• Current Assignee: United States Surgical Corporation (Medtronic Plc)
• Original Assignee: United States Surgical Corporation (Medtronic Plc)
• Inventors: Zhang, Guanghui, Gruskin, Elliott A., Connolly, Kevin, Buechter, Douglas D.
• Granted Patent: US 6,958,223 B2
• Time in Patent Office: Days
• US Class Current: 435/69.1
• CPC Class Codes: C07K 14/4725 Proteoglycans, e.g. aggreccan
• CPC Class Codes: C07K 14/495 Transforming growth factor [TGF]
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C07K 14/75 Fibrinogen
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12P 21/02 having a known sequence of two or more amino acids, e.g. glutathione

Abstract

Incorporation of certain amino acid analogs into polypeptides produced by cells which do not ordinarily provide polypeptides containing such amino acid analogs is accomplished by subjecting the cells to growth media containing such amino acid analogs. The degree of incorporation can be regulated by adjusting the concentration of amino acid analogs in the media and/or by adjusting osmolality of the media. Such incorporation allows the chemical and physical characteristics of polypeptides to be altered and studied. In addition, nucleic acid and corresponding proteins including a domain from a physiologically active peptide and a domain from an extracellular matrix protein which is capable of providing a self-aggregate are provided. Human extracellular matrix proteins capable of providing a self-aggregate collagen are provided which are produced by prokaryotic cells. Preferred codon usage is employed to produce extracellular matrix proteins in prokaryotics.

Claims

1. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof capable of providing a self aggregate in a cell which does not ordinarily hydroxylate proline comprising

providing a nucleic acid sequence encoding the EMP or fragment thereof which has been optimized for expression in the cell by substitution of codons preferred by the cell for naturally occurring codons not preferred by the cell;

incorporating the nucleic acid sequence into the cell;

providing hypertonic growth media containing at least one amino acid selected from the group consisting of trans-4-hydroxyproline and 3-hydroxyproline; and

contacting the cell with the growth media wherein the at least one amino acid is assimilated into the cell and incorporated into the EMP or fragment thereof.

2. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherein the EMP is selected from the group consisting of human collagen, fibrinogen, fibronectin and collagen-like peptide.

3. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherein the cell is a prokaryote.

4. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 3 wherein the prokaryote is E. coli.

5. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 2 wherein the human collagen is Type I (α

1).

6. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 5 wherein the nucleic acid encoding human collagen Type I (α

1) includes the sequence shown in SEQ. ID. NO. 19.

7. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 2 wherein the human collagen is Type I (α

2).

8. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 7 wherein the nucleic acid encoding human collagen type I (α

2) includes the sequence shown in SEQ. ID. NO. 31.

9. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherein the nucleic acid encoding the EMP includes the sequence shown in SEQ. ID. NO. 43.

10. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherein the nucleic acid encoding the EMP includes the sequence shown in SEQ. ID. NO. 46.

11. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherein the nucleic acid sequence includes nucleic acid encoding a physiologically active peptide.

13. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherein the EMP or fragment thereof is a collagen-like peptide.

14. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 13 wherein the EN or fragment thereof includes the amino acid sequence depicted in SEQ. ID. NO. 4.

15. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 13 wherein the EMP includes the amino acid sequence depicted in SEQ. ID. NO. 40.

16. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherein the EMP includes the amino acid sequence depicted in SEQ. ID. NO. 44.

17. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherien the EMP is a collagen fragment including the amino acid sequence depicted in SEQ. ID. NO. 26.

18. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 1 wherien the EMP is a collagen fragment including the amino acid sequence depicted in SEQ. ID. NO. 46.

12. A method of producing an Extracellular Matrix Protein (EMP) or fragment thereof according to claim 111 wherein the physiologically active peptide is selected from the group consisting of bone morphogenic protein, transforming growth factor −

β and

decorin.